SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ:FLDM) today introduced HeliosTM, a CyTOF® platform that enables system-level biology at single-cell resolution, on an accessible, expandable system designed for breakthrough discovery. Mass cytometry has catalyzed the revolution of single-cell proteomics, enabling the most comprehensive understanding of cell phenotypes, signaling pathways and function. Helios dawns as the most advanced tool for cellular exploration with streamlined workflows and multi-modal capabilities for advancing single-cell biology.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
